Drug intelligence / Profile preview

LY2149371

Development stage: Discontinued
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

**LY2149371** is a small molecule drug developed by Eli Lilly and Company as a selective **glucagon receptor antagonist**. It was investigated for the treatment of **type 2 diabetes mellitus** by blocking glucagon signaling to reduce hepatic glucose output and improve glycemic control. The compound advanced to early clinical development but was discontinued due to insufficient efficacy or other development challenges typical in diabetes drug discovery.

Targets

GCGR (Glucagon receptor)

Beyond the preview

Go deeper on LY2149371.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY2149371.

Explore the full profile